Charles Schwab Investment Management Inc. reduced its stake in shares of MetLife, Inc. (NYSE:MET - Free Report) by 0.9% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,876,531 shares of the financial services provider's stock after selling 36,877 shares during the period. Charles Schwab Investment Management Inc. owned 0.58% of MetLife worth $311,247,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its stake in shares of MetLife by 33.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 24,663,239 shares of the financial services provider's stock valued at $2,019,427,000 after purchasing an additional 6,213,923 shares during the last quarter. Bank of New York Mellon Corp lifted its position in MetLife by 0.4% during the 1st quarter. Bank of New York Mellon Corp now owns 8,862,835 shares of the financial services provider's stock worth $711,597,000 after acquiring an additional 36,177 shares during the last quarter. Northern Trust Corp lifted its position in MetLife by 15.7% during the 4th quarter. Northern Trust Corp now owns 7,052,202 shares of the financial services provider's stock worth $577,434,000 after acquiring an additional 958,458 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in MetLife by 4.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 6,434,737 shares of the financial services provider's stock worth $526,869,000 after acquiring an additional 290,734 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in MetLife by 12.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,113,108 shares of the financial services provider's stock worth $418,661,000 after acquiring an additional 564,383 shares during the last quarter. 94.99% of the stock is currently owned by hedge funds and other institutional investors.
MetLife Price Performance
NYSE MET traded up $1.26 on Tuesday, reaching $76.56. The company's stock had a trading volume of 3,656,843 shares, compared to its average volume of 3,436,330. The firm has a market cap of $51.39 billion, a PE ratio of 12.98, a price-to-earnings-growth ratio of 0.67 and a beta of 0.85. The business has a 50-day moving average price of $78.02 and a 200 day moving average price of $78.92. MetLife, Inc. has a 52 week low of $65.21 and a 52 week high of $89.05. The company has a current ratio of 0.16, a quick ratio of 0.16 and a debt-to-equity ratio of 0.57.
MetLife (NYSE:MET - Get Free Report) last posted its earnings results on Wednesday, August 6th. The financial services provider reported $2.02 earnings per share for the quarter, missing analysts' consensus estimates of $2.32 by ($0.30). The business had revenue of $17.34 billion during the quarter, compared to the consensus estimate of $18.58 billion. MetLife had a net margin of 5.83% and a return on equity of 19.88%. The business's revenue was down 2.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.28 EPS. Sell-side analysts expect that MetLife, Inc. will post 9.65 EPS for the current year.
MetLife Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 5th will be paid a dividend of $0.5675 per share. This represents a $2.27 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Tuesday, August 5th. MetLife's dividend payout ratio is currently 38.47%.
MetLife announced that its Board of Directors has authorized a stock buyback program on Wednesday, April 30th that permits the company to buyback $3.00 billion in outstanding shares. This buyback authorization permits the financial services provider to purchase up to 5.9% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's management believes its shares are undervalued.
Analysts Set New Price Targets
A number of research analysts have recently commented on MET shares. Wells Fargo & Company reaffirmed an "overweight" rating and set a $97.00 price objective (up previously from $94.00) on shares of MetLife in a research report on Thursday, July 10th. Barclays upped their price objective on shares of MetLife from $88.00 to $94.00 and gave the company an "overweight" rating in a research report on Monday, July 7th. UBS Group cut their price objective on shares of MetLife from $94.00 to $91.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. JPMorgan Chase & Co. upped their price objective on shares of MetLife from $86.00 to $95.00 and gave the company an "overweight" rating in a research report on Tuesday, July 8th. Finally, Wall Street Zen lowered shares of MetLife from a "buy" rating to a "hold" rating in a research report on Saturday, May 24th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, MetLife has a consensus rating of "Moderate Buy" and an average target price of $96.00.
Read Our Latest Report on MetLife
MetLife Profile
(
Free Report)
MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.
Recommended Stories

Before you consider MetLife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MetLife wasn't on the list.
While MetLife currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report